Trial Profile
An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2024
Price :
$35
*
At a glance
- Drugs Fitusiran (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; Registrational
- Acronyms ATLAS-OLE
- Sponsors Sanofi Genzyme
- 08 Jan 2024 Planned End Date changed from 18 Dec 2026 to 5 Nov 2026.
- 08 Jan 2024 Planned primary completion date changed from 18 Dec 2026 to 5 Nov 2026.
- 15 Dec 2022 According to an Alnylam Pharmaceuticals media release, the company plans to report data from this study in late 2023.